/
Updates in Lymphoma From Recent Congresses Updates in Lymphoma From Recent Congresses

Updates in Lymphoma From Recent Congresses - PowerPoint Presentation

lindy-dunigan
lindy-dunigan . @lindy-dunigan
Follow
348 views
Uploaded On 2018-11-06

Updates in Lymphoma From Recent Congresses - PPT Presentation

Therapeutic Targets in CLL Venetoclax in Patients With 17p Deletion Venetoclax in Patients With 17p Deletion cont Bendamustine Plus Obinutuzumab Ibrutinib Plus Ublituximab Updates in Lymphoma From Recent Congresses ID: 717369

rituximab cont congresses lymphoma cont rituximab lymphoma congresses updates trial cell lenalidomide abbreviations venetoclax pembrolizumab ibrutinib bright tazemetostat year

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "Updates in Lymphoma From Recent Congress..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1

Updates in Lymphoma From Recent CongressesSlide2

Therapeutic Targets in CLLSlide3

Venetoclax in Patients With 17p DeletionSlide4

Venetoclax in Patients With 17p Deletion (cont)Slide5

Bendamustine Plus ObinutuzumabSlide6

Ibrutinib Plus UblituximabSlide7

Updates in Lymphoma From Recent CongressesSlide8

EZH2

Inhibitor TazemetostatSlide9

EZH2

Inhibitor Tazemetostat (cont)Slide10

Gene Expression Profiling in the Prediction of Disease ProgressionSlide11

Causes of Death in FLSlide12

Causes of Death in FL (cont)Slide13

FL TransformationSlide14

Cumulative Incidence by Rituximab Use

(n = 6340) Slide15

Pembrolizumab Plus RituximabSlide16

Pembrolizumab Plus Rituximab: ResultsSlide17

Lenalidomide Plus RituximabSlide18

Lenalidomide Plus Rituximab (cont)Slide19

Updates in Lymphoma From Recent CongressesSlide20

The SCHOLAR-1 StudySlide21

CAR T-Cell Therapy: CTL019Slide22

CAR T-Cell Therapy: ZUMA-1 Trial of KTE-C19 Slide23

Clinical ConclusionsSlide24

Pembrolizumab For Relapsed/Refractory Primary Mediastinal B-Cell LymphomaSlide25

Updates in Lymphoma From Recent CongressesSlide26

The BRIGHT Trial: 5-Year Follow-UpSlide27

The BRIGHT Trial: 5-Year Follow-Up (cont)Slide28

Single-Agent Lenalidomide in Relapsed or Refractory MCLSlide29

Ibrutinib vs TemsirolimusSlide30

Combining Ibrutinib With VenetoclaxSlide31

AbbreviationsSlide32

Abbreviations (cont)Slide33

Abbreviations (cont)